Recall Unsafe Drugs Act of 2017
Latest action · Feb 17, 2017 Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 16, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Recall Unsafe Drugs Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require producers of medications to notify the Food and Drug Administration (FDA) of the identity and location of a medication if the producer has reason to believe: (1) that the medication is adulterated or misbranded; and (2) there is a reasonable probability that the use or consumption of, or exposure to, the medication will cause a threat of serious adverse health consequences or death to humans or animals.
The FDA may: (1) request that the distributor of a medication that is in violation of the FFDCA voluntarily recall the medication; (2) require the distributor of a medication that may cause serious adverse health consequences to immediately cease distribution of the medication; (3) recall a medication for which distribution has been ceased after giving the distributor an opportunity for an informal hearing; and (4) immediately recall a medication that presents an imminent threat of serious adverse health consequences. Distributors may appeal these FDA orders.
In the case of a recall, the FDA must notify consumers and state and local health officials to whom the medication was, or may have been, distributed.
Medication distributors must have a recall plan in effect.
Cosponsors 4
Members who signed on, in the order they did. Signatures ran from Mar 8, 2017 to Oct 25, 2017.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-RI | James R. Langevin | Mar 8, 2017 | |
| D-MD | Jamie Raskin | Mar 8, 2017 | |
| D-TX | Lloyd Doggett | Mar 8, 2017 | |
| D-NY | Louise McIntosh Slaughter | Oct 25, 2017 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Feb 16, 2017 |
| Commerce, Manufacturing, and Trade Subcommittee | Referred Feb 17, 2017 |
Actions 3
Everything that happened, newest first.
- Feb 17, 2017Referred to the Subcommittee on Digital Commerce and Consumer Protection.
- Feb 16, 2017Introduced in House
- Feb 16, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 28, February 16, 2017, page H1303.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 5578 | Recall Unsafe Drugs Act of 2020 | Reintroduced Bill | Jan 10, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To provide for the mandatory recall of drugs regulated by the Food and Drug Administration.
- Short Titles as Introduced
- Recall Unsafe Drugs Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Feb 16, 2017Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.